Immutep (ASX:IMM) said initial pharmacological data from a placebo-controlled, double-blind first-in-human phase 1 study evaluating its IMP761 treatment candidate, a lymphocyte-activation gene-3 agonist antibody for autoimmune diseases, showed positive results and a continued favorable safety profile, according to a Monday Australian bourse filing.
The company reported no treatment-related adverse events in healthy participants from the highest dosing level to date at 0.9 milligrams per kilogram (mg/kg) of IMP761, which is being considered as a potential treatment for rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.
The inhibition of T-cell infiltration in the skin at day 10 following a neoantigen rechallenge reached 80% at the same dosing level.
The firm is continuing with single ascending dose levels of 2.5 mg/kg, 7 mg/kg, and 14 mg/kg, the filing said. Additional data from the phase one study is expected in the second half.
Immutep's shares fell past 1% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.